What are you searching for?


4 Min read

Global Natural Killer Cells Therapeutics Market to Grow at 17% during 2021 - 2029

Published On 10 Feb 2022 06:17 AM


According to Absolute Markets Insights report, antibody directed NK cell therapies is projected to witness fastest growth over the forecast period (2021-2029) in the natural killer cells therapeutics market. The growth in the antibody directed NK cell therapies segment can be attributed to increasing usage of monoclonal antibodies (mAbs) for different diseases as well as an easy availability of such drugs. The natural killer (NK) cells plays a significant role in cancer immunotherapies that comprises of tumor-antigen targeting with the help of monoclonal antibodies (mAbs). Moreover, NK cell therapies segment is expected to witness substantial growth during the forecast period due to several advances in NK cells therapies such as adoptive therapy, target recognition, and improvement in cellular cytotoxicity.

View Full Report Link: https://www.absolutemarketsinsights.com/reports/Natural-Killer-Cells-Therapeutics-Market-2021---2029-862

The global natural killer cells therapeutics market is witnessing advancement owing to rapid research and development initiatives in the sector. For instance, in January 2022, ONK Therapeutics, an Ireland-based cell therapy company is evolving the industry to optimally engineer NK cells to perform better in the hostile tumour microenvironment. Also, the company has announced an infusion of $21.5 million to push their NK-powered programs towards IND-enabling studies.  Further, natural killer cells have become an emerging and thriving cancer cell therapy sector. Hence, the demand for revolutionized cancer treatment in recent times has led to a large number of developments in the industry. Such developments are projected to create lucrative growth opportunities for the global natural killer cells therapeutics market over the projected period. For instance, in February 2021, Cytovia Therapeutics, Inc., a biopharmaceutical company that develops allogeneic “off-the-shelf” gene-edited Natural Killer (NK) & Chimeric Antigen Receptor (CAR)-NK cells and Cellectis, a biopharmaceutical company that focuses on development of immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), entered into a strategic R&D collaboration to develop TALEN gene-edited iPSC NK and CAR-NK cells.

A substantial increase has been observed in North American and European deals surrounding NK cell therapies in cancer treatment. For instance, in November 2021, Kiadis Pharma, a biopharmaceutical company in the Netherlands was acquired by Sanofi, a French multinational healthcare company, just months after an €875M (USD 1,001.34 Mn) licensing deal with the same company. In addition to this, Artiva Therapeutics, the NK cell therapy firm launched a collaboration worth up to €1.5B (USD 1.72 Bn) with MSD, an American multinational pharmaceutical company. Furthermore, the number of smaller European companies have seen rise in number of NK cell therapies deals in the past several months. For instance, Onward Therapeutics, the Swiss company, invested in EMERCell, the French NK cell therapy developer, becoming the majority shareholder.

Request Sample Copy of This Report: https://www.absolutemarketsinsights.com/request_sample.php?id=862

How Absolute Market Insights is unique in nature?

The research report on Natural Killer Cells Therapeutics Market will include extensive information based on the following pointers:

  • Global Market size and forecast values (2015 – 2029), in terms of revenue (US$ Million) by segments/sub-segments; wherein 2015 to 2019 has been considered as historic years, 2020 as the base year, while 2021 to 2029 has been considered as the forecast period.
  • Split of the market revenue (US$ Million) into all the relevant segments & sub-segments across all major regions/countries.
  • Market Determinants and Influencing Factors
  • Macro-Economic and Micro-Economic Indicators
  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
    • Challenges
  • Regulatory Landscape
  • Trends on Global Natural Killer Cells Therapeutics Market
  • Impact of Covid-19 on Global Natural Killer Cells Therapeutics Market
  • Porter’s Five Forces Analysis
  • Competitor Landscape
    • Market Share Analysis, 2020
    • Global Presence and Growth Strategies
  • The final report will include competitive product benchmarking which will include comparison of different products offered by different market participants on the basis of their features and capabilities that will help you to understand their market offerings. Furthermore, for each company, we will provide information regarding company details, company overview, product offerings, key developments, financial analysis, and SWOT analysis and business strategies.
  • Research study focusing on specific regions, including North America, Europe, Asia Pacific, Middle East & Africa and Latin America are also available.
  • The reports can be provided in different languages including Chinese, Korean, Japanese, German, Arabic, Russian, French, Spanish, and other languages.

Key Findings:

  • Natural killer cells therapeutics market participants are focusing on collaborations and research & development to improve their product line. For instance, in June 2021, ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, was awarded an Innovation Partnership Programme (IPP) grant by Enterprise Ireland (EI) to fund collaborative research at Trinity College Dublin, Ireland, to optimize the engineering and metabolism of NK cells for improved cancer therapies.
  • Cancer accounted for the highest share in natural killer cells therapeutics market in 2020. The growth in this segment is attributed to the significant growth in adoption of NK cell therapies for different types of cancers such as acute myeloid leukemia, cutaneous T cell lymphoma, Hodgkin's lymphoma, solid tumors, hematologic malignancies, and head & neck cancer
  • Peripheral blood accounted for the highest market share in natural killer cells therapeutics market in 2020. The growth in this segment can be attributed to the fact that peripheral blood collected by apheresis is the main source of donor NK cells.
  • Hospitals & clinics accounted for the highest market share in natural killer cells therapeutics market in 2020. Growth of this segment is primarily driven by the fact that the hospitals and clinics are the major place to diagnose cancer and infectious diseases among others.
  • Asia-Pacific is projected to witness highest growth rate in the global natural killer cells therapeutics market during the forecast period. Growth of this region is mainly driven by a number of factors such as surge in geriatric population, improvement in healthcare facilities, and upsurge in number of patients suffering from cancer. In addition to this, emerging economies such as India and China are heavily spending on the development of their medical and healthcare infrastructure, which is contributing towards the region’s growth.

Enquiry Before Buying: https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=862

Competitor Insights:

The key companies profiled in the global natural killer cells therapeutics market are mentioned below:

  • Acepodia Inc.
  • Affimed GmbH
  • Artiva Biotherapeutics, Inc.
  • Bellicum Phamaceuticals, Inc.
  • Cytovia Therapeutics
  • Dragonfly Therapeutics
  • EMERCell
  • Fate Therapeutics
  • Fortress Biotech, Inc.
  • Glycostem
  • ImmunityBio, Inc.
  • Innate Pharma S.A.
  • Kiadis Pharma
  • Nkarta, Inc.
  • NKGen Biotech
  • NKMAX Co., Ltd.
  • ONK Therapeutics Limited
  • Other Market Participants

Global Natural Killer Cells Therapeutics Market:

  • By Type:
  • NK Cell Therapies
  • Antibody Directed NK Cell Therapies
  • By Therapeutic Indication:
  • Cancer
      • Solid Tumors
        • Colorectal Cancer
        • Breast Cancer
        • Others
      • Hematological Malignancies
        • Acute Myeloid Leukemia (AML)
        • Multiple Myeloma (MM)
        • Others
  • Viral Infections
  • Autoimmune Diseases
  • Neurodegenerative Diseases
  • Others
  • By Source: 
  • Peripheral Blood
  • Umbilical Cord Blood
  • Induced Pluripotent Stem Cell (iPSC)
  • Others
  • By End Users: 
  • Hospitals & Clinics
  • Research Institutes
  • Others
  • By Region
  • North America
      • U.S.
      • Canada
      • Mexico
      • Rest of North America
  • Europe
      • France
      • The UK
      • Spain
      • Germany
      • Italy
      • Nordic Countries
        • Denmark
        • Finland
        • Iceland
        • Sweden
        • Norway
      • Benelux Union
        • Belgium
        • The Netherlands
        • Luxembourg
      • Rest of Europe
  • Asia Pacific
      • China
      • Japan
      • India
      • New Zealand
      • Australia
      • South Korea
      • Southeast Asia
        • Indonesia
        • Thailand
        • Malaysia
        • Singapore
        • Rest of Southeast Asia
      • Rest of Asia Pacific
  • Middle East & Africa
      • Saudi Arabia
      • UAE
      • Egypt
      • Kuwait
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
      • Brazil
      • Argentina
      • Rest of Latin America

Purchase the Report: https://www.absolutemarketsinsights.com/checkout?id=862

Related Reports:

  1. Global HyperRAM Market 2021 – 2029
  2. Global Pharmaceutical Contract Sales Outsourcing (CSO) Market 2021 - 2029

Contact Us:

Company: Absolute Markets Insights
Email Id: [email protected]
Phone: IN +91-740-024-2424 , US +1-510-420-1213
Contact Name: Shreyas Tanna
Website: www.absolutemarketsinsights.com/


Press Release Provided By: Absolute Markets Insights